Loading clinical trials...
Loading clinical trials...
Intentional Coronary Revascularization Versus Conservative Therapy in Patients Undergoing Peripheral Artery Revascularization Due to Critical Limb Ischemia
The objective of the INCORPORATE trial is to evaluate whether an intentional invasive strategy with ischemia targeted, reasonably complete coronary revascularization and optimal medical therapy is superior as compared to a primary conservative approach and optimal medical therapy alone in terms of spontaneous myocardial infarct-free and overall survival in patients with severe peripheral artery disease, underwent peripheral artery revascularization due to critical limb ischemia. The INCORPORATE trial is designed to be non-blinded, open-label, prospective 1:1 randomized controlled multicentric trial.
Age
18 - 100 years
Sex
ALL
Healthy Volunteers
No
Div. Cardiology and Div. Angiology, Dept. Medicine, Medical University Graz
Graz, Austria
Bacs-Kiskun County Hospital
Kecskemét, Hungary
Start Date
July 11, 2018
Primary Completion Date
August 31, 2021
Completion Date
August 31, 2022
Last Updated
November 6, 2018
650
ESTIMATED participants
FFR-guided coronary revascularization
DEVICE
Lead Sponsor
Medical University of Graz
NCT07010029
NCT06503640
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions